Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Merck KGaA May Withdraw Research from Portugal over Debt-Report

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/09/2012 | 08:28am CEST

German chemical company Merck KGaA (>> Merck KGaA) may withdraw future investments for research projects in Portugal worth tens of millions of euros unless the government hospitals stick to the agreed-upon debt repayments, German daily newspaper Financial Times Deutschland reports Monday.

Merck Portugal's manager Fritz Sacher told the paper the company's research projects are long-term and require mutual trust as a basis. "The Portuguese government's lacking payment habits undermine this trust," he is quoted as saying.

Portuguese government hospitals owe the pharmaceutical industry a total of more than 1.5 billion euros ($1.84 billion) and companies have to wait nearly 550 days on average until invoices are paid, FTD reports.

Some companies, including Roche Holding AG (ROG.VX), have already halted the sale of medications on credit to highly indebted countries like Portugal, Greece, Spain and Italy until outstanding debts are paid, the paper notes, but for many companies such drastic steps are difficult as they carry responsibility for people's wellbeing.

Withdrawing research projects is a way of putting pressure on the government, as Portugal is an attractive location for research investments, FTD says. "The conditions for certain research and human studies are as good as in the U.S., but it's significantly more cost-effective in Portugal," Sacher told the paper.

Newspaper website: http://www.ftd.de

Write to the Frankfurt Bureau at [email protected]

Stocks mentioned in the article : Merck KGaA
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK KGAA
04/28 MERCK KGAA : Darmstadt, Germany Publishes Corporate Responsibility Report 2016
04/25 MERCK : MilliporeSigma Collaborates with LabCentral to Foster Biotech Startups
04/25 Fresenius picks up M&A pace with Akorn, Merck KGaA deals
04/25DJFRESENIUS : Makes Two Acquisitions to Boost Kabi Clinical Unit
04/24 MERCK : Darmstadt, Germany Divests Biosimilars Business to Fresenius
04/24DJFresenius Kabi To Strengthen And Diversify Product Portfolio By Acquiring Ako..
04/24 AWARE FOR ALL : CISCRP's Clinical Research Education Event Returning to Houston ..
04/20 MERCK : Researchers from Merck KGaA Describe Findings in Granulocytes (Compariso..
04/20 Merck to expand online business 'dramatically'
04/18 MERCK : Darmstadt, Germany Furthers Commitment Towards Elimination of Schistosom..
More news
Sector news : Specialty & Advanced Pharmaceuticals
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Specialty & Advanced Pharmaceuticals
News from SeekingAlpha
04/27 Fresenius Medical (FMS) Acquires Akorn (AKRX) And Merck KGaA's (MKGAF) Biosim..
04/26 Fresenius Shows Biotech How To Get The Deals Done
04/25 FOCUS ON EUROPE : Gearing Up For Q1 Results!
04/15 The Market Is Going To Fall - My Dividend Growth Shopping List
03/31 AMERICAN ASSOCIATION FOR CANCER RESE : Combinations, Oncolytic Viruses, And More
Advertisement
Financials (€)
Sales 2017 15 591 M
EBIT 2017 3 327 M
Net income 2017 1 869 M
Debt 2017 9 712 M
Yield 2017 1,18%
P/E ratio 2017 24,83
P/E ratio 2018 21,22
EV / Sales 2017 1,52x
EV / Sales 2018 1,34x
Capitalization 13 932 M
More Financials
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 111 €
Spread / Average Target 2,9%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stefan Oschmann Chief Executive Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA8.72%15 177
ABBVIE INC5.30%105 080
KYOWA HAKKO KIRIN CO L..18.17%9 882
JAZZ PHARMACEUTICALS P..46.09%9 559
CONVATEC GROUP PLC31.30%7 732
MALLINCKRODT PLC-5.82%4 912
More Results